MétaCan
Menu
Back to cohort
Record W3193922103 · doi:10.1093/eurheartj/ehab499

Sacubitril–valsartan as a treatment for apparent resistant hypertension in patients with heart failure and preserved ejection fraction

2021· article· en· W3193922103 on OpenAlexaff
Alice M. Jackson, Pardeep S. Jhund, Inder S. Anand, Hans‐Dirk Düngen, Carolyn S.P. Lam, Marty Lefkowitz, Gerard C.M. Linssen, Lars H. Lund, Aldo P. Maggioni, Marc A. Pfeffer, Jean L. Rouleau, José Francisco Kerr Saraiva, Michele Senni, Orly Vardeny, Magnus Wijkman, Mehmet Birhan Yılmaz, Yoshihiko Saito, Michael R. Zile, Scott D. Solomon, John J.V. McMurray

Bibliographic record

VenueEuropean Heart Journal · 2021
Typearticle
Languageen
FieldMedicine
TopicHeart Failure Treatment and Management
Canadian institutionsUniversité de MontréalMontreal Heart Institute
FundersDaiichi Sankyo EuropeNational Heart, Lung, and Blood InstituteDefense Acquisition Program AdministrationCelladon CorporationMedical Research CouncilJapan Agency for Medical Research and DevelopmentOtsuka PharmaceuticalAmgen Astellas BiopharmaAmerican RegentEli Lilly JapanChugai PharmaceuticalNovartis PharmaNational Institutes of HealthTeijin PharmaSvenska LäkaresällskapetPfizer JapanShionogiRespicardiaMyoKardiaBayer YakuhinBritish Heart FoundationMinistry of Education, Culture, Sports, Science and TechnologySanofi PasteurUniversity of OxfordPfizerModernaMitsubishi Tanabe Pharma CorporationNational Medical Research CouncilBoehringer Ingelheim JapanUniversity of GlasgowToa EiyoKowa CompanyActelion PharmaceuticalsNippon ShinyakuNihon Medi-PhysicsJapan Society for the Promotion of ScienceAstellas PharmaCytokineticsIronwood Pharmaceuticals, IncorporatedDainippon Sumitomo PharmaBoston Scientific CorporationBristol-Myers SquibbOno PharmaceuticalEli Lilly and CompanyAlnylam PharmaceuticalsAstraZenecaCSL BehringNovo NordiskGilead SciencesSanofiLivaNovaGlaxoSmithKlineAmgen
KeywordsMedicineValsartanSacubitrilBlood pressureCardiologySacubitril, ValsartanInternal medicineHeart failureEjection fractionHeart failure with preserved ejection fractionDiabetes mellitusEndocrinology

Abstract

fetched live from OpenAlex

AIMS: Patients with heart failure and preserved ejection fraction (HFpEF) frequently have difficult-to-control hypertension. We examined the effect of neprilysin inhibition on 'apparent resistant hypertension' in patients with HFpEF in the PARAGON-HF trial, which compared the effect of sacubitril-valsartan with valsartan. METHODS AND RESULTS: In this post hoc analysis, patients were categorized according to systolic blood pressure at the end of the valsartan run-in (n = 4795). 'Apparent resistant hypertension' was defined as systolic blood pressure ≥140 mmHg (≥135 mmHg if diabetes) despite treatment with valsartan, a calcium channel blocker, and a diuretic. 'Apparent mineralocorticoid receptor antagonist (MRA)-resistant' hypertension was defined as systolic blood pressure ≥140 mmHg (≥135 mmHg if diabetes) despite the above treatments and an MRA. The primary outcome in the PARAGON-HF trial was a composite of total hospitalizations for heart failure and death from cardiovascular causes. We examined clinical endpoints and the safety of sacubitril-valsartan according to the hypertension category. We also examined reductions in blood pressure from the end of valsartan run-in to Weeks 4 and 16 after randomization. Overall, 731 patients (15.2%) had apparent resistant hypertension and 135 (2.8%) had apparent MRA-resistant hypertension. The rate of the primary outcome was higher in patients with apparent resistant hypertension [17.3; 95% confidence interval (CI) 15.6-19.1 per 100 person-years] compared to those with a controlled systolic blood pressure (13.4; 12.7-14.3 per 100 person-years), with an adjusted rate ratio of 1.28 (95% CI 1.05-1.57). The reduction in systolic blood pressure at Weeks 4 and 16, respectively, was greater with sacubitril-valsartan vs. valsartan in patients with apparent resistant hypertension [-4.8 (-7.0 to -2.5) and 3.9 (-6.6 to -1.3) mmHg] and apparent MRA-resistant hypertension [-8.8 (-14.0 to -3.5) and -6.3 (-12.5 to -0.1) mmHg]. The proportion of patients with apparent resistant hypertension achieving a controlled systolic blood pressure by Week 16 was 47.9% in the sacubitril-valsartan group and 34.3% in the valsartan group [adjusted odds ratio (OR) 1.78, 95% CI 1.30-2.43]. In patients with apparent MRA-resistant hypertension, the respective proportions were 43.6% vs. 28.4% (adjusted OR 2.63, 95% CI 1.18-5.89). CONCLUSION: Sacubitril-valsartan may be useful in treating apparent resistant hypertension in patients with HFpEF, even in those who continue to have an elevated blood pressure despite treatment with at least four antihypertensive drug classes, including an MRA. CLINICAL TRIAL REGISTRATION: PARAGON-HF: ClinicalTrials.gov Identifier NCT01920711.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame distilled prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.

metaresearch head score (Codex)0.000
metaresearch head score (Gemma)0.000
Version: codex-gemma-dda1882f352aValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.268
Threshold uncertainty score0.571

Codex and Gemma teacher scores by category

CategoryCodexGemma
Metaresearch0.0000.000
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0000.000
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0000.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.035
GPT teacher head0.277
Teacher spread0.242 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one teacher head, not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations154
Published2021
Admission routes1
Has abstractyes

Explore more

Same venueEuropean Heart JournalSame topicHeart Failure Treatment and ManagementFrench-language works237,207